Long‑Term Follow‑Up of Adjuvant Imatinib for Localized Gastrointestinal Stromal Tumors
Adjuvant imatinib improves relapse‑free survival in patients with localized gastrointestinal stromal tumor, particularly in the high‑risk subgroup.
These results support the continued use of 3‑year adjuvant imatinib as standard of care for high‑risk GIST patients, emphasizing the importance of patient selection and treatment duration.
Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Kapcsolódó jelek
- Disproportionality analysis of adverse events associated with tyrosine kinase inhibitors in gastrointestinal stromal tumors in the FDA adverse event reporting system
- Review of Genomic Testing and SDH Deficiency in Gastrointestinal Stromal Tumors: Getting to the GIST
- Molecular Tailored Therapeutic Options for Advanced Gastrointestinal Stromal Tumors (GISTs): Current Practice and Future Perspectives
- Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach
- UK clinical practice guidelines for the management of gastrointestinal stromal tumours (GIST)